Income Taxes - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Income Tax Examination [Line Items]
Capitalized research and development	$ 82,389,000	$ 51,159,000
Gross deferred tax assets	366,357,000	263,358,000
Valuation allowance	359,440,000	248,420,000
Increase (decrease) in valuation allowance on deferred tax assets	111,000,000	68,300,000
Penalties or interest accrued on income taxes	0	0
ImmPACT Bio USA Inc.
Income Tax Examination [Line Items]
Gross deferred tax assets	39,600,000
Deferred tax assets, foreign tax attribute carryforwards	1,400,000
ImmPACT Bio USA Inc. | Capitalized Research Costs and Tax Attribute Carryforwards
Income Tax Examination [Line Items]
Valuation allowance	39,600,000
ImmPACT Bio USA Inc. | Tax Credit Carryforwads
Income Tax Examination [Line Items]
Valuation allowance	1,400,000
Tax Year 2028 | Capital Loss Carryforward
Income Tax Examination [Line Items]
Tax credit carryforwards	52,500,000
Federal and State
Income Tax Examination [Line Items]
Tax credit carryforwards	43,600,000	24,200,000
Federal
Income Tax Examination [Line Items]
Operating loss carryforwards not subject to expiration	599,200,000	$ 455,200,000
State
Income Tax Examination [Line Items]
Operating loss carryforwards subject to expiration	702,900,000
Foreign Tax Jurisdiction
Income Tax Examination [Line Items]
Operating loss carryforwards not subject to expiration	$ 5,800,000